Flagship Pioneering Unveils Mirai Bio to Provide Fully Integrated End-to-End Genetic Medicine Development Capabilities for the Biotech Industry
Foghorn Therapeutics Inc. (NASDAQ: FHTX) had its price target raised by analysts at Morgan Stanley from $6.00 to $9.00. They now have an "equal weight" rating on the stock.
Strength Seen in Foghorn Therapeutics (FHTX): Can Its 9.5% Jump Turn into More Strength? [Yahoo! Finance]
Foghorn Therapeutics Inc. (NASDAQ: FHTX) is now covered by analysts at Jefferies Financial Group Inc.. They set a "buy" rating and a $18.00 price target on the stock.
Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer